Aaron Tachibana, serving as both Chief Financial Officer and Chief Operating Officer at Personalis, Inc. (NASDAQ: PSNL), completed a transaction involving the sale of 40,000 shares of the company's common stock on June 4, 2026. The aggregate value of this divestment reached $480,400. The execution of these sales occurred at a weighted average price of $12.01 per share, with individual transaction prices varying between $12.00 and $12.10. This specific trade was facilitated through a Rule 10b5-1 trading plan that Tachibana established on August 7, 2025.
Alongside the sale, Tachibana simultaneously acquired 40,000 shares of Personalis common stock. This acquisition was achieved by exercising stock options priced at $9.16 per share, resulting in a total cost of $366,400 for the executive. The options utilized for this exercise were fully vested and exercisable at the time. Post-transaction, Tachibana's direct holdings in Personalis common stock stand at 198,833 shares, accompanied by 28,832 stock options.
The timing of this insider activity coincides with a period of heightened price movement for Personalis shares. Over the previous year, the stock price has increased by more than 106%, a surge that persists despite the company continuing to report financial losses. Market analysis from InvestingPro indicates that the stock is currently trading above its calculated Fair Value, categorizing it among equities that may be overvalued. The platform also notes 11 additional ProTips for investors, highlighting the company's robust cash position and recent adjustments by analysts. A detailed Pro Research Report is available for those seeking deeper insights into Personalis and over 1,400 other US stocks.
In recent operational updates, Personalis Inc. reported first-quarter revenue figures that exceeded consensus estimates. This financial performance was driven significantly by the NeXT Personal minimal residual disease (MRD) test, which demonstrated a 258% year-over-year growth rate and a 26% quarter-over-quarter increase. During the first quarter, the test was ordered by over 1,000 oncologists.
Despite these positive operational metrics, analyst sentiment shows mixed pricing targets. BTIG revised its price target for Personalis downward from $13 to $11, though it maintained a Buy rating on the stock. Conversely, Needham reiterated its Buy rating with a $12 price target, citing the impressive MRD growth as a primary factor in its positive outlook.
Strategic advancements continue for Personalis through regulatory milestones. The Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program has expanded coverage for the NeXT Personal test. This new coverage includes monitoring treatment response to neoadjuvant therapy for patients with Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer. Additionally, the expansion covers immunotherapy monitoring for patients with late-stage solid tumors. These coverage expansions represent significant progress in broadening the test's application within clinical settings.
Corporate governance activities also proceeded with the annual meeting of stockholders. A quorum was successfully achieved, with 87.76% of outstanding shares represented during the virtual meeting. Shareholders voted on three proposals during this session, indicating ongoing strategic decisions and advancements within the company.
Market data reflects recent trading activity, with the stock closing at 10.75, down 1.350 or 11.16%. After-hours trading saw the price move to 10.87, up 0.120 or 1.12%. These fluctuations underscore the dynamic nature of the stock's recent performance.